Table 2.
Clinical characteristics of patients with and without new‐onset AF during the follow‐up period among the 207 HCM patients without AF at registration
| New‐onset AF (+) (n = 31) | New‐onset AF (−) (n = 176) | P | |
|---|---|---|---|
| Age at registration, years | 64 ± 12 | 60 ± 16 | 0.234 |
| Gender: male, n (%) | 24 (77%) | 115 (65%) | 0.187 |
| Age at diagnosis of HCM, years | 57 ± 14 | 55 ± 17 | 0.591 |
| Reason for diagnosis of HCM: symptoms, n (%) | 13 (42%) | 57 (32%) | 0.300 |
| Family history of HCM, n (%) | 8 (26%) | 46 (26%) | 0.969 |
| Family history of sudden death, n (%) | 6 (19%) | 32 (18%) | 0.876 |
| Symptoms at registration, n (%) | |||
| NYHA functional class: III/IV | 0 (0%) | 3 (2%) | 1.000 |
| Palpitation | 12 (39%) | 26 (15%) | 0.002 |
| Echocardiographic data at registration | |||
| Subtype, n (%) | 0.763 | ||
| HOCM | 5 (16%) | 25 (14%) | |
| MVO | 0 (0%) | 6 (3%) | |
| End‐stage | 1 (3%) | 3 (2%) | |
| Apical HCM | 5 (16%) | 37 (21%) | |
| HNCM | 20 (65%) | 105 (60%) | |
| Presence of LV outflow obstruction, n (%) | 4 (13%) | 23 (13%) | 1.000 |
| Maximum LV wall thickness, mm | 18.2 ± 4.4 | 19.2 ± 4.0 | 0.187 |
| LV end‐diastolic diameter, mm | 47.7 ± 6.5 | 45.2 ± 5.6 | 0.032 |
| LV Fractional shortening, % | 41.4 ± 8.7 | 42.5 ± 7.5 | 0.465 |
| Left atrial diameter, mm | 44.8 ± 5.5 | 41.3 ± 6.1 | 0.003 |
| Significant mitral regurgitation, n (%) | 2 (6%) | 7 (4%) | 0.626 |
| Medications at registration, n (%) | |||
| Beta‐blocker | 15 (48%) | 55 (31%) | 0.063 |
| Calcium antagonist | 6 (19%) | 38 (22%) | 0.779 |
| ACEI or ARB | 7 (23%) | 36 (20%) | 0.788 |
| Diuretic | 2 (6%) | 10 (6%) | 0.697 |
| Amiodarone | 1 (3%) | 2 (1%) | 0.387 |
| Anti‐coagulation therapy | 4 (13%) | 2 (1%) | 0.005 |
ACEI, angiotensin‐converting enzyme inhibitor; AF, atrial fibrillation; ARB, angiotensin II receptor blocker; HCM, hypertrophic cardiomyopathy; HNCM, hypertrophic non‐obstructive cardiomyopathy (HCM without obstruction other than end‐stage HCM and apical HCM); HOCM, hypertrophic obstructive cardiomyopathy; MVO, midventricular obstruction; NYHA, New York Heart Association; LV, left ventricular.